DiaSorin S.p.A. (OTCMKTS:DSRLF) Given Consensus Rating of “Hold” by Analysts

Posted by Brian Himes on May 14th, 2026

Shares of DiaSorin S.p.A. (OTCMKTS:DSRLF – Get Free Report) have been given an average recommendation of “Hold” by the six brokerages that are currently covering the company, Marketbeat reports. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company.

A number of research firms recently weighed in on DSRLF. BNP Paribas Exane upgraded shares of DiaSorin to a “neutral” rating in a research note on Wednesday, January 28th. UBS Group lowered shares of DiaSorin from a “buy” rating to a “neutral” rating in a research note on Thursday, April 9th. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of DiaSorin in a research note on Tuesday, February 10th. Finally, Zacks Research upgraded shares of DiaSorin to a “hold” rating in a research note on Tuesday.

Check Out Our Latest Stock Analysis on DiaSorin

DiaSorin Stock Performance

DSRLF stock opened at $67.00 on Thursday. The company’s 50 day moving average price is $71.57 and its 200 day moving average price is $75.91. DiaSorin has a fifty-two week low of $66.50 and a fifty-two week high of $112.30.

About DiaSorin

(Get Free Report)

DiaSorin S.p.A. is an Italy‐based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over‐the‐counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.